Insulin
The safety of any drug needs to be well established to ensure the safety of the consumer. NBI’s oral insulin has been established to be safe through in vitro cytotoxicity studies in Caco-2 and HeLa cells. The NBI strategic innovation team brough in Dr Sandeep Jain, Dr Madhukar Saxena and Dr Amit Pal.
Dr Sandeep Jain
Dr. Sandeep has 11+ years of experience in pharmaceutical industry. His business acumen, entrepreneurial zeal, organizational skills and managerial abilities have enabled company to grow leaps and bounds and spread its wings across the globe.
He set out with a vision to create a global pharmaceutical company. Under his able and dynamic leadership, Oniosome has grown rapidly to attain newer milestones and the highest level of performance. He is the principal architect for the progress of the organization.
Dr. Sandeep is M. Pharm (Pharmaceuticals) graduate for about one decades of experience across Research & Development. He is well versed with the overall management of the company and possesses vast amount of hands-on experience in research and formulation development.
Dr Madhukar Saxena
Dr Saxena is working as Head R&D at AAL Biosciences Research Pvt Ltd with demonstrated excellence in Pre-clinical Research and Innovative Healthcare Product development. He has more than 15 years of experience in endocrinology, molecular genetics, and Invitro cell culture studies.
He has worked with reputed Government organizations, universities, CRO’s and journal publishing companies. He was involved in NBI’s Cholesterol formulation animal studies including development of animal model, histopathology and biochemical investigations.
Dr Amit Kumar Pal
Dr Pal is working as a Lab Director at AAL Biosciences Research Pvt Ltd with a demonstrated history of working around drug development including pre-clinical Toxicology and Research and Development activities of more than 15 years along with clinical regulatory affairs, pharmacovigilance/ safety, R&D quality, biostatistics.
He also has technical expertise in Pharmaceutical, Clinical Biochemistry, Molecular Biology, Clinical Pathology, Quality Management. He was involved with NBI for preclinical safety and efficacy study of Cholesterol formulation.